As described earlier, ABL1 inhibitors (e.g., imatinib, dasatinib, nilotinib, and ponatinib) are used to treat patients with BCR/ABL-positive ALL and ABL1-class fusions that occasionally occur in BCR/ABL-like ALL and T-ALL [40,53,55]. Here, ABL1 is linked to acute lymphoblastic leukemia.